MARKET NEWS

The FDA Expands Collaboration With CN Bio to Investigate Lung-on-a-Chip Model for Inhaled Drug Evaluation Applications
Syneos Health Launches “Lab to Life” Enterprise Partnership With Komodo Health
Scipher Applies Spectra Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE 327 Against All Six ESKAPE Pathogens
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery & Development Programs
ScienceMedia & Area9 Lyceum Partner to Deliver Clinical Education for Life Sciences on Area9 Rhapsode Adaptive Learning Platform

  FEATURED EDITORIAL

  COMPANY PROFILE

At Pharmaceutics International, Inc. (Pii), our motto is “challenges frame opportunities.” We are a US-based contract development and manufacturing organization (CDMO) that has “walked in your shoes” and has a passion for solving problems efficiently with the highest quality standards. Emphasizing a collaborative relationship with our clients, Pii’s experts embrace the art and science of drug development and manufacturing. Our outcome is to deliver better results faster for our clients and their patients. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Nemera’s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Aché’s NSAIDs & Dry Eye Formulations

Nemera’s Preservative-Free Multi-Dose Eyedropper Approved in Brazil for Aché’s NSAIDs & Dry Eye Formulations

Nemera is excited to announce that its multidose eye dropper Novelia has been approved by ANVISA for the preservative-free formulations CLILON [1] (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug….

Vectura & Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Vectura & Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Vectura Group plc and Inspira Pharmaceuticals Limited recently announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the potential treatment of….

Takara Bio Europe AB & PanCryos Announce Licensing Agreement to Enable Development of Cell-Based Therapy for Diabetes

Takara Bio Europe AB & PanCryos Announce Licensing Agreement to Enable Development of Cell-Based Therapy for Diabetes

Takara Bio Europe AB (TBEAB) and PanCryos recently announce they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines…..

Gerresheimer Presents Innovative SensAIR Platform for First Drug Delivery Device for Biologics

Gerresheimer Presents Innovative SensAIR Platform for First Drug Delivery Device for Biologics

With SensAIR, Gerresheimer presents for the first time a new platform for on-body infusion pumps that can deliver drugs of higher viscosity, such as monoclonal antibodies (mAbs), with precise dosing and safety….

Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing

Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing

Catalent and Promethera Biosciences recently announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 19 – Nasal Drug Delivery
May 26 – Lyophilization Manufacturing